[Statistical studies on the value of various surveillance methods for the diagnosis and prognosis of "small-for-date" infants (proceedings)].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to W Geiger.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Five volunteers with normal ovarian cycles received oral doses of 2 X 2.5 mg or 3 X 2.5 mg bromocriptin (CB 154)/day respectively. The treatment started at the onset of menstruation and lasted on complete cycle. In addition to the decrease of prolactin secretion, a reduction of plasma progesterone concentrations during the corpus luteum phase was demonstrated. This fall of progesterone seemed to be preferentially due to bromocriptin-induced hypoprolactinaemia and not to direct ovarian effects of the drug.
Serial determinations of FSH, LH, estradiol-17 beta and progesterone in plasma and of total gonadotropins, total estrogens and pregnanediol in urine were performed in 10 adolescent girls between 15 and 19 years of age. Two types of menstrual cycles could be distinguished. The first type is characterized by a nearly normal pattern of FSH, while a preovulatory rise of estradiol-17 beta and an LH-peak is still missing. Only few days prior to menstrual bleeding a small rise of estradiol and progesterone in plasma as well as of estrogens and pregnanediol in urine can be seen, being equivalent to a short luteinization of the follicle without ovulation taking place. The second type already shows all criteria of a regular ovulatory cycle. However the plasma level of LH, estradiol and progesterone and the excretion of estrogens and pregnanediol are still below the average values of control cycles of adult women. On the basis of the hormonal pattern and a shortened luteal phase, a relative insufficiency of this type of cycles is still evident. These studies demonstrate, that the cyclic ovarian function postmenarchial develops gradually and that the onset of ovulation is a marked step in this development. This process of maturition, which is due to the gradual development of the positive feedback of estrogens on the release of LH by the pituitary gland, allows to distinguish in adolescence between cycles before and after maturition of the feed-back mechanism in the ANS.
In healthy women (21-28 years) the influence of synthetic alpha-MSH upon the peripheral plasms levels of LH, FSH, progesterone and cortisol was determined during the corpus luteum phase of the menstrual cycle. As controls 3 women were given 6 intravenous infusions of 250 ml NaCl; 4 women received a total of 18 intravenous infusions of 5-20 mg alpha-MSH from 9.00 to 11.00 a.m. on the 5th and 7th hyperthermic day of the menstrual cycle. The blood levels of the hormones were usually followed for 24 h, and in two cases for 48 h. During and after the control as well as the experimental infusions with 5-20 mg alpha-MSH, no significant changes in the plasma concentrations of LH, FSH and progesterone were found. The cortisol concentrations, however, showed on the average a 2-fold increase over the initial values during the infusion of 5 mg and 10 mg alpha-MSH. During the control infusions they were not enhanced. One experiment was conducted with 20 mg alpha-MSH. The increase in the plasma cortisol levels following alpha-MSH administration generally seemed to be dose dependent, but statistically no significant differences regarding the increase in cortisol level could be detected between the 5 mg and 10 mg doses.
Explore the source record for details and available documents.
Mastodynia has previously been treated with gestagens or gestagen-based ovulation inhibitors with only marginal success. No other satisfactory therapy was available and in the search for a better treatment, the effectiveness of long term administration of the prolactin inhibitor bromocryptine (CB 154) to 15 patients was evaluated. Five of the subjects exhibited mammary secretion as well as mastodynia which, accorind to palpatorial, cytological and X-ray criteria, was not caused by intraductal pathology. After two to four weeks treatment with 5 mg CB 154 per day ten patients recovered fully, three showed some improvement and two were totally resistant to the treatment. Plasma prolactin levels during the follicular stage measured prior to treatment were in the normal range. All the patients continued to ovulate during the course of treatment despite the irrefutable fact that prolactin release from the pituitary was inhibited. Since there was a similar inhibition of prolactin secretion in the two patients who were resistant to treatment, it would seem that prolactin though probably very important, cannot be the only decisive factor in the hormonal control of mystodynia. Further observations showed that the premenstrual syndrome can also be successfully treated with CB 154. Upon withdrawal of treatment the possibility or relapse must be considered.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
2 Bromo-alpha-ergocryptine, a specific prolactin inhibitor, was administered to 9 patients suffering from galactorrhea-amenorrhea syndrome of varying aetiology. Plasma levels of FSH, LH, prolactin, total estrogens and progesterone were measured by radioimmunoassy before and after treatment initiation. Prior to treatment, plasma prolactin levels were in all cases supraphysiological. FSH and LH levels were, with the exception of one patient, in the low cyclic range. One patient had subnormal gonadotropin levels, presumably reflecting hypophyseal insufficiency following surgical removal of a pituitary adenoma. Mean plasma levels of total estrogens were in the lower normal range. Administration of CB 154 led in all cases to a reduction of plasma prolactin levels. In eight cases, galactorrhea was suppressed during the first month of treatment. Eight patients menstruated and seven ovulated as indicated by the basal body temperature (BBT) or plasma progesterone measurement. The postoperative hypophyseal tumor patient did not, with the exception of galactorrhea suppression, respond to treatment, presumably due to hypophyseal insufficiency. 2 patients conceived during the course of treatment. One patient, who developed galactorrhea-amenorrhea syndrome as a result of psychopharmacological drug administration received 7,5 mg/day CB 154. Prolactin secretion, as indicated by plasma levels, was inhibited but the inhibitation was much slower in onset than that exhibited by the other patients and this patient ovulated only after 5 months of treatment. Upon withdrawal of CB 154 therapy after 6 to 7 months, the patients redeveloped galactorrhea-amenorrhea syndrome, so that a definitive cure could not be demonstrated.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.